A Form 4 filed on August 11, 2026, reports that Veronica Sanchez Bulis, VP and Corporate Controller of Lyell Immunopharma, Inc. (NASDAQ:LYEL), disposed of 621 shares of common stock on August 10, 2026, to cover tax withholding obligations from the settlement of vested restricted stock units.
Key Highlights
- Reporting person: Veronica Sanchez Bulis, VP and Corporate Controller of Lyell Immunopharma, Inc.
- Transaction date: August 10, 2026, with 621 shares of common stock disposed of (transaction code S).
- Weighted average sale price: $14.34 per share, with individual sale prices ranging from $14.20 to $14.34 per share.
- Purpose: Shares were automatically sold to cover tax withholding obligations from the settlement of vested restricted stock units, according to the filing.
- Remaining ownership: Following the transaction, Bulis directly beneficially owned 14,799 shares of common stock.
Tax Withholding Sale Details for Lyell Immunopharma Corporate Controller
According to the Form 4 filing, Veronica Sanchez Bulis, who serves as VP and Corporate Controller at Lyell Immunopharma, Inc., disposed of 621 shares of the company's common stock on August 10, 2026. The filing identifies the transaction code as "S" and notes that the shares were "automatically sold to cover tax withholding obligation from settlement of vested restricted stock units."
The filing states that the price reported reflects the weighted average of the shares sold, at $14.34 per share, and that the actual sale prices ranged from $14.20 to $14.34 per share. The filing further notes that upon request from the SEC staff, the issuer, or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price within that range. The transaction was a direct disposal, and no derivative securities transactions were reported.
Following the reported transaction, Bulis directly beneficially owned 14,799 shares of Lyell Immunopharma common stock, according to the filing. The Form 4 was signed by Mark Meltz as Attorney-in-Fact and filed on August 11, 2026.
What Was Disclosed
The filing disclosed an automatic sale of 621 shares of Lyell Immunopharma common stock by VP and Corporate Controller Veronica Sanchez Bulis on August 10, 2026, at a weighted average price of $14.34, solely to satisfy a tax withholding requirement upon restricted stock unit vesting.



Please wait processing your request...